It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent

It has been shown that triple antiplatelet therapy with cilostazol results in better clinical outcomes than dual therapy in patients treated with a first-generation drug-eluting stent (DES); however, it is unclear whether triple antiplatelet therapy has a similar efficacy after the implantation of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ju-Youn, Choi, Yun-Seok, Kwon, Ami, Chung, Woo-Baek, Park, Chul-Soo, Kim, Hee-Yeol, Chang, Kiyuk, Lee, Man-Young, Chung, Wook-Sung, Seung, Ki-Bae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652826/
https://www.ncbi.nlm.nih.gov/pubmed/26579817
http://dx.doi.org/10.1097/MD.0000000000002062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652826/
https://www.ncbi.nlm.nih.gov/pubmed/26579817
http://dx.doi.org/10.1097/MD.0000000000002062

Ejemplares similares